gvs 111 has been researched along with prolylglycine in 2 studies
| Studies (gvs 111) | Trials (gvs 111) | Recent Studies (post-2010) (gvs 111) | Studies (prolylglycine) | Trials (prolylglycine) | Recent Studies (post-2010) (prolylglycine) |
|---|---|---|---|---|---|
| 91 | 2 | 31 | 51 | 0 | 19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gudasheva, TA; Lutsenko, VK; Vukolova, MN | 1 |
| Gudasheva, TA; Ivanova, TV; Ostrovskaya, RU; Seredenin, SB; Vakhitova, YV; Zainullina, LF | 1 |
2 other study(ies) available for gvs 111 and prolylglycine
| Article | Year |
|---|---|
Cyclopropyl glycine and proline-containing preparation noopept evoke two types of membrane potential responses in synaptoneurosomes.
Topics: Animals; Calcium; Dipeptides; Dose-Response Relationship, Drug; Male; Membrane Potentials; Nootropic Agents; Peptides; Proline; Rats; Synaptosomes | 2003 |
Drug with Neuroprotective Properties Noopept Does Not Stimulate Cell Proliferation.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dipeptides; Flow Cytometry; HEK293 Cells; Humans; Ki-67 Antigen; Neuroprotective Agents; Peptides | 2019 |